A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) (NCT07011043)
A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)
🩺 Plain-English Summary (8th-Grade Level)
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Who can join: Review the eligibility criteria below.
Location: Climb Bio Investigative Site #100104 — Allen, Texas
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Climb Bio Investigative Site #100104 — Allen, Texas
- Climb Bio Investigative Site #100101 — San Antonio, Texas
- Climb Bio Investigative Site# 359101 — Plovdiv,
- Climb Bio Investigative Site# 359102 — Sofia,
- Climb Bio Investigative Site #995102 — Tbilisi,
- Climb Bio Investigative Site #995101 — Tbilisi,
- Climb Bio Investigative Site# 300102 — Exochi, Thessaloniki
- Climb Bio Investigative Site# 300103 — Thessaloniki, Thessaloniki
- Climb Bio Investigative Site #100103 — Caguas,
- Climb Bio Investigative Site# 400101 — Cluj-Napoca,
- Climb Bio Investigative Site# 340101 — Sabadell, Barcelona
- Climb Bio Investigative Site# 340102 — A Coruña,
- Climb Bio Investigative Site #380102 — Ivano-Frankivsk,
- Climb Bio Investigative Site #380103 — Kyiv,
- Climb Bio Investigative Site #380106 — Kyiv,
- Climb Bio Investigative Site #380101 — Ternopil,
- Climb Bio Investigative Site #380104 — Vinnytsia,
- Climb Bio Investigative Site #380105 — Vinnytsia,
📞 Contact the Study Coordinator
Phone: (866) 857-2596
Email: clinicaltrials@climbbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.